ANXA5 and neoplasm: To evaluate the influence of AnxA5 administration on the therapeutic antitumor efficacy and immunogenicity of tumor-specific immunization following cisplatin treatment, we utilized a well-established preclinical tumor model with defined tumor-specific antigen, the TC-1 tumor model.